神经认知障碍:对已批准 (2008-2024) 和正在开发的第三阶段药物的系统审查
Jayant Totlani1, Muhammad Arsalan Bashir2, Laurel Tay2
1Dr. Totlani is with the Virginia Commonwealth University Health System in Richmond, Virginia and Cedars-Sinai Medical Center in Los Angeles, California.
Innovations in clinical neuroscience
|February 6, 2026
概括
本综述检查了FDA批准的和管道中的药物治疗神经认知障碍 (NCD) 从2008-2024. 虽然进步包括新的阿尔茨海默氏症疗法,但在获取和副作用方面仍然存在挑战.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 公共卫生 公共卫生
背景情况:
- 像阿尔茨海默氏症 (AD) 这样的神经认知障碍 (NCD) 构成了日益严重的全球健康挑战.
- 全球数百万人受到非传染性疾病的影响,需要有效的药理干预措施.
研究的目的:
- 系统地审查FDA批准的非传染性疾病的药物 (2008-2024年).
- 为了检查NCDs的第三阶段管道药物.
- 详细说明这些治疗方法的作用机制,疗效和不良影响.
主要方法:
- 在PubMed (2008-2024) 的系统文献搜索.
- 关键词:神经认知,痴呆,阿尔茨海默病,心理药理学,药物,制药.
- 对符合条件的研究进行独立审查和达成共识.
主要成果:
- 八种药物已批准用于重症/轻症非传染性疾病 (单克隆抗体,乙胆酶抑制剂,NMDA对抗剂,抗精神病药物).
- 在非传染性疾病 (生物药物,神经保护药物) 的第三阶段试验中,有22种管道药物.
- 没有FDA批准的或用于痴呆症的III期药物被发现.
结论:
- 在NCD药理管理方面取得了重大进展,包括疾病修饰的AD疗法.
- 目前的治疗方法提供症状缓解;挑战包括副作用和成本.
- 有前途的管道剂需要进一步的试验来证实有效性和安全性.
相关概念视频
Endocarditis III: Medical Management
261
Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...
261
Myocarditis III: Medical Management
217
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
217
Pericarditis III: Medical Management
362
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
362
Mitral Stenosis III: Medical Management
312
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
312
Aortic Regurgitation III: Medical Management
457
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
457
Mitral Regurgitation III: Medical Management
358
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
358


